{"id":"ptc-pertuzumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pertuzumab is a humanized monoclonal antibody that binds to HER2 and prevents its heterodimerization with other HER family receptors, blocking downstream signaling. The combination with PTC (the specific agent is not clearly defined in available literature) likely aims to provide complementary HER2-pathway inhibition or target additional oncogenic pathways in HER2-positive tumors.","oneSentence":"PTC+Pertuzumab combines a PTC (likely a protein tyrosine kinase inhibitor or similar agent) with pertuzumab, a HER2-targeting monoclonal antibody that blocks HER2 dimerization to inhibit tumor growth.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:30:46.799Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive breast cancer (phase 3)"}]},"trialDetails":[{"nctId":"NCT03820063","phase":"PHASE2","title":"Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2019-02-27","conditions":"Breast Cancer","enrollment":462},{"nctId":"NCT01996267","phase":"PHASE3","title":"Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2013-12","conditions":"Breast Cancer, HER2 Positive","enrollment":437},{"nctId":"NCT04750122","phase":"PHASE1, PHASE2","title":"Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2021-03-28","conditions":"HER2-positive Early Breast Cancer","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Paclitaxel; 80 mg/m2; day 1,8","Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1","Carboplatin; AUC=6; day 1","Pertuzumab; 420 mg (loading dose 840 mg); day 1"],"phase":"phase_3","status":"active","brandName":"PTC+Pertuzumab","genericName":"PTC+Pertuzumab","companyName":"The Netherlands Cancer Institute","companyId":"the-netherlands-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PTC+Pertuzumab combines a PTC (likely a protein tyrosine kinase inhibitor or similar agent) with pertuzumab, a HER2-targeting monoclonal antibody that blocks HER2 dimerization to inhibit tumor growth. Used for HER2-positive breast cancer (phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}